Terns Pharmaceuticals, Inc. Share Price
TERNTerns Pharmaceuticals, Inc. Stock Performance
Open $52.95 | Prev. Close $52.94 | Circuit Range N/A |
Day Range $52.92 - $52.96 | Year Range $2.65 - $53.17 | Volume 1,03,638 |
Average Traded $52.93 |
Terns Pharmaceuticals, Inc. Share Price Chart
About Terns Pharmaceuticals, Inc.
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in Phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase IIa clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis (MASH); and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for obesity, as well as TERN-800 series of small-molecule glucose-dependent insulinotropic polypeptide receptor (GIPR) modulators for obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.
Terns Pharmaceuticals, Inc. Historical Data
| Day | Open | Close | Change % |
|---|---|---|---|
28-Apr-26 | $52.95 | $52.93 | -0.04% |
27-Apr-26 | $52.91 | $52.95 | +0.11% |
24-Apr-26 | $52.88 | $52.89 | +0.10% |
23-Apr-26 | $52.83 | $52.84 | -0.02% |
22-Apr-26 | $52.79 | $52.84 | +0.00% |
21-Apr-26 | $52.72 | $52.84 | +0.22% |
20-Apr-26 | $52.66 | $52.73 | +0.15% |